CL2022001989A1 - Formulación de anticuerpos estable - Google Patents

Formulación de anticuerpos estable

Info

Publication number
CL2022001989A1
CL2022001989A1 CL2022001989A CL2022001989A CL2022001989A1 CL 2022001989 A1 CL2022001989 A1 CL 2022001989A1 CL 2022001989 A CL2022001989 A CL 2022001989A CL 2022001989 A CL2022001989 A CL 2022001989A CL 2022001989 A1 CL2022001989 A1 CL 2022001989A1
Authority
CL
Chile
Prior art keywords
antibody
ebov
present disclosure
storage
pharmaceutical formulations
Prior art date
Application number
CL2022001989A
Other languages
English (en)
Spanish (es)
Inventor
Cao Yuan
Liu Dingjiang
Xu Long
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CL2022001989A1 publication Critical patent/CL2022001989A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CL2022001989A 2020-01-24 2022-07-22 Formulación de anticuerpos estable CL2022001989A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202062965786P 2020-01-24 2020-01-24

Publications (1)

Publication Number Publication Date
CL2022001989A1 true CL2022001989A1 (es) 2023-03-31

Family

ID=74858743

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2022001989A CL2022001989A1 (es) 2020-01-24 2022-07-22 Formulación de anticuerpos estable
CL2023002560A CL2023002560A1 (es) 2020-01-24 2023-08-30 Formulación de anticuerpos estable

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2023002560A CL2023002560A1 (es) 2020-01-24 2023-08-30 Formulación de anticuerpos estable

Country Status (13)

Country Link
US (2) US12337199B2 (cg-RX-API-DMAC7.html)
EP (1) EP4093435A1 (cg-RX-API-DMAC7.html)
JP (2) JP7674369B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220131923A (cg-RX-API-DMAC7.html)
CN (1) CN115243718A (cg-RX-API-DMAC7.html)
AU (1) AU2021210942A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022014240A2 (cg-RX-API-DMAC7.html)
CA (1) CA3162569A1 (cg-RX-API-DMAC7.html)
CL (2) CL2022001989A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022010254A2 (cg-RX-API-DMAC7.html)
IL (1) IL294375B2 (cg-RX-API-DMAC7.html)
MX (1) MX2022008949A (cg-RX-API-DMAC7.html)
WO (1) WO2021150829A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112545886A (zh) 2015-03-10 2021-03-26 里珍纳龙药品有限公司 无菌刺穿系统和方法
US20200148750A1 (en) 2016-07-21 2020-05-14 Emory University Ebola Virus Antibodies and Binding Agents Derived Therefrom
CA3055583A1 (en) 2017-05-05 2018-11-08 Regeneron Pharmaceuticals, Inc. Auto-injector
MX2022008949A (es) * 2020-01-24 2022-08-15 Regeneron Pharma Formulacion de anticuerpos estable.
USD1007676S1 (en) 2021-11-16 2023-12-12 Regeneron Pharmaceuticals, Inc. Wearable autoinjector
WO2024259313A1 (en) 2023-06-16 2024-12-19 Regeneron Pharamceuticals, Inc. Medical device packaging and related methods
TW202529831A (zh) 2023-10-02 2025-08-01 美商再生元醫藥公司 藥物遞輸裝置安全系統
WO2025171492A1 (en) 2024-02-14 2025-08-21 Alpha-9 Oncology Inc. Stable radiopharmaceutical compositions and uses thereof
US20260221053A1 (en) 2025-01-29 2026-07-30 Regeneron Pharmaceuticals, Inc. Drug delivery devices, safety systems, training devices, and methods of use thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0747045B2 (ja) 1986-10-15 1995-05-24 株式会社大協精工 積層した注射器用滑栓
JP3100727B2 (ja) 1992-01-23 2000-10-23 株式会社大協精工 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
JP3172057B2 (ja) 1995-04-05 2001-06-04 株式会社大協精工 ラミネートゴム栓
JP3512349B2 (ja) 1999-01-29 2004-03-29 株式会社大協精工 柱状ゴム要素の成形型
AU7089600A (en) 1999-08-30 2001-03-26 U.S. Army Medical Research Institute Of Infectious Diseases Monoclonal antibodies and vaccines against epitopes on the ebola virus glycoprotein
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
US6875433B2 (en) 2002-08-23 2005-04-05 The United States Of America As Represented By The Secretary Of The Army Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein
EP2262832A4 (en) 2008-02-01 2011-03-09 Ca Minister Health & Welfare MONOCLONAL ANTIBODIES TO EBOLA AND MARBURG VIRUSES
AR070315A1 (es) * 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
WO2010048615A2 (en) 2008-10-24 2010-04-29 The Government Of The United States Of America As Represented By The Secretary, Department Of Health & Human Services, Center For Disease Control And Prevention Human ebola virus species and compositions and methods thereof
WO2012135408A1 (en) 2011-03-31 2012-10-04 Merck Sharp & Dohme Corp. Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
WO2014031718A1 (en) 2012-08-23 2014-02-27 Merck Sharp & Dohme Corp. Stable formulations of antibodies to tslp
JP6041580B2 (ja) * 2012-08-28 2016-12-14 京セラ株式会社 電子機器、制御方法、及び制御プログラム
TWI710573B (zh) 2015-01-26 2020-11-21 美商再生元醫藥公司 抗伊波拉病毒醣蛋白之人類抗體
HRP20201334T1 (hr) 2015-04-17 2020-11-27 Bristol-Myers Squibb Company Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba
SG11201909941QA (en) * 2017-05-02 2019-11-28 Merck Sharp & Dohme Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
US20210054079A1 (en) * 2018-04-25 2021-02-25 Medimmune Limited Formulations of human anti-pd-li antibodies
MX2022008949A (es) * 2020-01-24 2022-08-15 Regeneron Pharma Formulacion de anticuerpos estable.

Also Published As

Publication number Publication date
EP4093435A1 (en) 2022-11-30
JP2025090691A (ja) 2025-06-17
IL294375B2 (en) 2026-06-01
CA3162569A1 (en) 2021-07-29
WO2021150829A1 (en) 2021-07-29
AU2021210942A1 (en) 2022-07-14
IL294375A (en) 2022-08-01
BR112022014240A2 (pt) 2022-12-13
MX2022008949A (es) 2022-08-15
US20250288665A1 (en) 2025-09-18
JP2023511080A (ja) 2023-03-16
CL2023002560A1 (es) 2024-03-01
CO2022010254A2 (es) 2022-08-09
IL294375B1 (en) 2026-02-01
US12337199B2 (en) 2025-06-24
CN115243718A (zh) 2022-10-25
KR20220131923A (ko) 2022-09-29
JP7674369B2 (ja) 2025-05-09
US20210252146A1 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
CO2022010254A2 (es) Formulación de anticuerpos estable
CO2019011021A2 (es) Formulacion estable de anticuerpos
ES2391798T3 (es) Composición líquida farmacéutica de toxina botulínica con estabilidad mejorada
CO2021011648A2 (es) Formulaciones estabilizadas que contienen anticuerpos anti-il-33
CO2020013552A2 (es) Formulación de anticuerpos
CU20190015A7 (es) Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad y composiciones farmacéuticas que las comprenden
MX344294B (es) Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r).
JP2017222654A5 (cg-RX-API-DMAC7.html)
CU20210081A7 (es) Composición de partículas de arn lipoplejo
AR108631A1 (es) Formulación de neurotoxinas
ATE554792T1 (de) Stabiles wachstumshormon-flüssigformulierung
MX2021002935A (es) Formulacion de anticuerpos contra csf-1r.
CO2024014835A2 (es) Formulaciones de anticuerpos contra el receptor de interleucina 4 (il-4r)
CO7111300A2 (es) Formulación de anticuerpos
ZA202204982B (en) Stable formulation of integrin antibody
MX2022014650A (es) Formulacion que contiene anticuerpo.
UY33652A (es) Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4(il-ar)
JP7837512B2 (ja) ウイルス安定化剤、ウイルス安定化剤用ゼラチン加水分解物およびウイルス含有組成物
BR112022004674A2 (pt) Ácido canforsulfônico e combinações do mesmo com excipientes catiônicos como agentes de redução de viscosidade em formulações de proteína altamente concentradas
CL2025001546A1 (es) Composición de insulina de acción rápida (variantes)
CL2024003444A1 (es) Formulación farmacéutica líquida estable que comprende un anticuerpo biespecífico anti-cd20/cd3 humano.
BR112022024932A2 (pt) Vacina contra vírus da influenza a suína compreendendo um constructo de ácido nucleico que possui uma ordem específica de genes
AR127750A1 (es) Una composición antimicrobiana
CL2022003586A1 (es) Formulaciones de anticuerpo de activina a y métodos para utilizarlas
UY37260A (es) Formulación de neurotoxina que comprende un tensioactivo, un aminoácido seleccionado de triptófano o tirosina, y un tampón